Blueprint Medicines (BPMC) Receives a Buy from Leerink Partners

Leerink Partners analyst Andrew Berens maintained a Buy rating on Blueprint Medicines (BPMCResearch Report) on February 8 and set a price target of $93.00. The company’s shares closed last Monday at $81.45.

According to TipRanks.com, Berens ‘ ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -8.9% and a 42.2% success rate. Berens covers the Healthcare sector, focusing on stocks such as Forma Therapeutics Holdings, Turning Point Therapeutics, and Deciphera Pharmaceuticals.

Currently, the analyst consensus on Blueprint Medicines is a Moderate Buy with an average price target of $113.70, a 38.1% upside from current levels. In a report issued on January 24, Stifel Nicolaus also upgraded the stock to Buy with a $95.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Based on Blueprint Medicines’ latest earnings release for the quarter ending September 30, the company reported a quarterly revenue of $24.19 million and GAAP net loss of $117 million. In comparison, last year the company earned revenue of $745 million and had a net profit of $634 million.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Blueprint Medicines Corp. is a precision therapy company. It focuses on medicines to improve the lives of patients with genomically defined cancers, rare diseases and cancer immunotherapy. The company was founded by Chris Varma, Nicholas B. Lydon, Brian Druker, and Alexis Borisy on October 14, 2008 and is headquartered in Cambridge, MA.

Read More on BPMC:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More

Latest News Feed